Urinary incontinence-pharmacotherapy options

Annals of Medicine

Volumn 43, Issue 6, 2011, Pages 461-476

  Smith, Ariana L ^a,b   Wein, Alan J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Penn Urology   (United States)

Author keywords

Antimuscarinics; Over active bladder; Pharmacologic treatment; Stress urinary incontinence; Urgency urinary incontinence; Urinary incontinence

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ATROPINE; BELLADONNA ALKALOID PLUS OPIATE; BOTULINUM TOXIN; DARIFENACIN; DESMOPRESSIN; DULOXETINE; EPHEDRINE; EPHEDRINE SULFATE; ESTROGEN; FESOTERODINE; IMIPRAMINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PSEUDOEPHEDRINE; SOLIFENACIN; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; TROSPIUM CHLORIDE;

ANXIETY DISORDER; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ARTICLE; BLADDER CAPACITY; BLADDER FILLING; BLOOD PRESSURE; BLURRED VISION; CARDIOTOXICITY; COGNITIVE DEFECT; CONSTIPATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; EVENING DOSAGE; FATIGUE; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; INSOMNIA; MANIA; META ANALYSIS (TOPIC); NAUSEA; OVERACTIVE BLADDER; PARKINSONISM; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; STRESS INCONTINENCE; TACHYCARDIA; TREMOR; URINARY URGENCY; URINE INCONTINENCE; WEAKNESS; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; DRUG APPROVAL; HUMANS; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; URINARY INCONTINENCE, STRESS; URINARY INCONTINENCE, URGE;

EID: 79960182226     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2011.564203     Document Type: Article

References (128)

1. Haylen BT, de Ridder D, Freeman RM, et al. International Urogynecological Association; International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic fl oor dysfunction. Neurourol Urodyn. 2010;29:4-20.
2. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standarisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167-78. (Pubitemid 34195211)
3. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008; 54:543-62.
4. Andersson KE. New pharmacologic targets for the treatment of the overactive bladder: an update. Urology. 2004; 63(Suppl 3A):32-41.
5. Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein AJ, editors. Incontinence. 4th ed. Paris: Health Publication Ltd; 2009. p. 631-700.
6. Fenner DE, Trowbridge ER, Patel DA, et al. Establishing the prevalence of incontinence study: racial differences in women ' s patterns of urinary incontinence. J Urol. 2008; 179:1455-60.
7. Milsom I, Altman D, Lapitan MC, Nelson R, Sillen U, Thom D. Epidemiology of urinary (UI) and faecal (FI) incontinence and pelvic organ prolapse (POP). In: Abrams P, Cardozo L, Khoury S, Wein AJ, editors. Incontinence. 4th ed. Paris: Health Publications Ltd; 2009. p. 37-111.
8. Koelbl H, Nitti V, Baessler K, Salvatore S, Sultan A, Yamaguchi O. Pathophysiology of urinary incontinence, faecal incontinence and pelvic organ prolapse. In: Abrams P, Cardozo L, Khoury S, Wein AJ, editors. Incontinence. 4th ed. Paris: Health Publication Ltd; 2009. p. 255-330.
9. Nitti VW, Combs AJ. Correlation of Valsalva leak point pressure with subjective degree of stress urinary incontinence in women. J Urol. 1996;155:281-5. (Pubitemid 126426482)
10. Blaivas JG, Olsson CA. Stress incontinence: classification and surgical approach. J Urol. 1988;139:727-31.
11. Wein AJ. Pathophysiology and classification of voiding dysfunction. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 9th ed. Philadelphia: Saunders; 2007. p. 1973-85.
12. DeLancey JO. Structural support of the urethra as it relates to stress urinary incontinence: the hammock hypothesis. Am J Obstet Gynecol. 1994;170:1713-20.
13. Wein AJ. Neuromuscular dysfunction of the lower urinary tract. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED, editors. Campbell's Urology. 6th ed. Philadelphia: Saunders; 1992. p. 573-642.
14. Wein AJ, Levin RM, Barrett DM. Voiding function: relevant anatomy, physiology, and pharmacology. In: Duckett JW, Howards ST, Grayhack JT, Gillenwater JY, editors. Adult and Pediatric Urology. St Louis: Mosby; 1991. p. 933-99.
15. Anderson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev. 1993: 253-308.
16. Anderson KE, Wein AJ. Pharmacology of the lower urinary tract: Basis for current and future treatments of urinary incontinence. Pharmacol Rev. 2004;56:581-631. (Pubitemid 40003785)
17. Jensen D Jr. Pharmacological studies of the uninhibited neurogenic bladder. Acta Neurol Scand. 1981;64:175-80.
18. Anderson KE, Yoshida M. Antimuscarinics and the overac-tive detrusor-which is the main mechanism of action? Eur Urol. 2003;43:1-5. (Pubitemid 36134308)
19. Chess-Williams R. Muscarinic receptors of the urinary bladder: Detrusor, urothelial and prejunctional. Auton Autacoid Pharmacol. 2002;22:133-45. (Pubitemid 36687563)
20. Yoshida M, Miyamae K, Iwashita H, et al. Management of detrusor dysfunction in the elderly: Changes in acetyl-choline and adenosine triphosphate release during aging. Urology. 2004;63(Suppl 1):17-23. (Pubitemid 38317358)
21. Andersson KE, Wein AJ. Pharmacologic management of storage and emptying failure. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 9th ed. Philadelphia: Saunders; 2007. p. 2091-123.
22. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100:987-1006. (Pubitemid 47537675)
23. Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet. 2003;42: 1243-85. (Pubitemid 37491488)
24. Witte LP, Mulder WM, de la Rosette JJ, et al. Muscarinic receptor antagonists for overactive bladder treatment: does one fi t all? Curr Opin Urol. 2009;19:13-19.
25. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective Efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol. 1998;104:988-93.
26. Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology. 2000;55(5A Suppl): 47-9, discussion 50.
27. Pesce F, Rubilotta E, D'Amica A, et al. Long-term anti-cholinergic therapy: duration and causes of discontinuation. Paris, France: International Continence Society; 2003.
28. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3:46-53.
29. Waldeck K, Larsson B, Andersson K-E. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol. 1997;157: 1093-7. (Pubitemid 27066324)
30. Th ü roff JW, Chartier E, Corcus J, et al. Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol. 1998;16(Suppl 1):S48-61. (Pubitemid 128742907)
31. Baigrie RJ, Kelleher JP, Fawcett KP, et al. Oxybutynin: is it safe? Br J Urol. 1988;62:319.
32. Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol. 1999; 39:289-96. (Pubitemid 29148552)
33. Chancellor MB, Appell RA, Sathyan G, et al. A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartate. Clin Ther. 2001;23:753.
34. Anderson R, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol. 1999;161:1809-12. (Pubitemid 29420737)
35. Corcos J, Casey R, Patrick A, et al. Uromax Study Group. A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing Efficacy with severity of dry mouth. BJU Int. 2006;97:520-7.
36. Dmochowski RR, Davila GW, Sinner NR, et al. Efficacy and safely of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol. 2002;168:580-6. (Pubitemid 34793301)
37. Davila GW, Daugherty CA, Sanders SW. A short-term, multi-center, randomized double-blind dose titration study of the Efficacy and anticholinergic side effects of transder-mal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol. 2001;166:150-1.
38. Dmochowski RR, Davila GW, Sinner NR, et al. Comparative Efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003; 62:237-42. (Pubitemid 36952069)
39. Cartwright R, Cardozo L. Transdermal oxybutynin: sticking to the facts. Eur Urol. 2007;51:907-14. (Pubitemid 46281437)
40. Connor JP, Betrus G, Fleming P, et al. Early cystometro-grams can predict the response to intravesical instillation of oxybutynin chloride in myelomeningocele patients. J Urol. 1994;151:1045-7. (Pubitemid 24083507)
41. Szollar SM, Lee SM. Intravesical oxybutynin for spinal cord injury patients. Spinal Cord. 1996;34:284-7. (Pubitemid 26188560)
42. Madersbacher H, Jilg G. Control of detrusor hyperrefl exia by the intravesical instillation of oxybutynin hydrochloride. Paraplegia. 1991;29:84-90.
43. Staskin DR, Dmochowski RR, Sand PK, et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol. 2009;181:1764-72.
44. Brynne N, Stahl MMS, Hallen B, et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther. 1997;35:287.
45. Nilvebrant L, Sundquist S, Gillberg PG. Tolterodine is not subtype (m1-m5) selective but exhibits functional bladder selectivity in vivo. Neurourol Urodyn. 1996;15:310-11.
46. van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once daily: Superior Efficacy and tolerability in the treatment of overactive bladder. Urology. 2001;57:414-21. (Pubitemid 32192963)
47. Hills CJ, Winter SA, Balfour JA. Tolterodine. Drugs. 1998; 55:813.
48. Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815-50. (Pubitemid 32385908)
49. Diefenbach K, Jaeger K, Wollny A, et al. Effect of toltero-dine on sleep structure modulated by CYP2D6 genotype. Sleep Med. 2008;9:579-82. (Pubitemid 351837477)
50. Elinoff V, Bavendam T, Glasser DB, et al. Symptom-specifi c Efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract. 2006;60:745-51. (Pubitemid 43811659)
51. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended release oxybutynin chloride and tolterodine tartrate in the treatment of over-active bladder: Results of the OBJECT study. Mayo Clin Proc. 2001;76:358-63. (Pubitemid 32248750)
52. Diokno AC, Appell RA, Sand PK, et al. OPERA Study Group. Prospective, randomized, double-blind study of the Efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial. Mayo Clin Proc. 2003;78: 687-95. (Pubitemid 36665898)
53. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: The antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin. 2002;18:177-84.
54. Song C, Park JT, Heo KO, et al. Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study. J Korean Med Sci. 2006;21:1060-3.
55. Mattiasson A, Blaakaer J, Høye K, et al. Tolterodine Scandinavian Study Group. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int. 2003;91:54-60.
56. Millard RJ; Asia Pacific Tolterodine Study Group. Clinical Efficacy of tolterodine with or without a simplifi ed pelvic fl oor exercise regimen. Neurourol Urodyn. 2004;23:48-53. (Pubitemid 38063953)
57. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol. 2001;41:636-44. (Pubitemid 32493358)
58. Kim Y, Yoshimura N, Masuda H, et al. Intravesical instillation of human urine after oral administration of trospium, tolterodine, and oxybutynin in a rat model of detrusor over-activity. BJU Int. 2006;97:400.
59. Stöhrer M, Bauer P, Giannetti BM, et al. Effect of trospium chloride on urodynamic parameters in patients with detru-sor hyperrefl exia due to spinal cord injuries: A multicenter placebo-controlled double-blind trial. Urol Int. 1991;47: 138-43.
60. Madersbacher H, Stöhrer M, Richter R, et al. Trospium chloride versus oxybutynin: A randomized double blind, multicenter trial in the treatment of detrusor hyperrefl exia. Br J Urol. 1995;75:452-6.
61. Allousi S, Laval K-U, Eckert R. Trospium chloride (Spasmo-lyt) in patients with motor urge syndrome (detru-sor instability): A double-blind, randomised, multicentre, placebo-controlled study. J Clin Res. 1998;1:439-51. (Pubitemid 29078044)
62. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicenter clinical trial to investigate long-term tolerability and Efficacy of trospium chloride in patients with detrusor instability. World J Urol. 2003;20:392-9. (Pubitemid 44175311)
63. Dmochowski RR, Sand PK, Zinner NR, Staskin DR. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology. 2008;71:449-54. (Pubitemid 351374733)
64. Fr ö hlich G, Burmeister S, Wiedemann A, Bulitta M. [Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle. A placebo controlled, randomized clinical test]. Arzneimittelforschung. 1998;48: 486-91. (Pubitemid 28247635)
65. Walter P, Grosse J, Bihr AM, et al. Bioavailability of trospium chloride after intravesical instillation in patients with neurogenic lower urinary tract dysfunction: A pilot study. Neurourol Urodyn. 1999;18:447-53. (Pubitemid 29468396)
66. Ikeda K, Kobayashi S, Suzuki M, et al. M(3) receptor antagonism by the novel antimuscarinic agent solif-enacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol. 2002;366:97-103. (Pubitemid 34762267)
67. Chapple CR, Arano P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-fi nding study. BJU Int. 2004;93:71-7. (Pubitemid 38112970)
68. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimus-carinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004;172(pt 1):1919-24. (Pubitemid 39363090)
69. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. STAR study group. A comparison of the Efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR Trial. Eur Urol. 2005;48:464-70. (Pubitemid 41188406)
70. Andersson KE. Potential benefi ts of muscarinic M3 receptor selectivity. Eur Urol. 2002;1:23.
71. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well tolerated once daily treatment for overactive bladder. Eur Urol. 2004;45: 420-9. (Pubitemid 38376197)
72. Chapple CR, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the Efficacy, toler-ability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int. 2005;95:993.
73. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol. 2005;173:493-8.
74. Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52:1204-12. (Pubitemid 47332062)
75. Ney P, Pandita RK, Newgreen DT, et al. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int. 2008;101: 1036-42. (Pubitemid 351422555)
76. Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother. 2008;9:1787-96.
77. Khullar V, Rovner ES, Dmochowski R, et al. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology. 2008;71:839-43.
78. Kelleher CJ, Tubaro A, Wang JT, et al. Impact of fesotero-dine on quality of life: pooled data from two randomized trials. BJU Int. 2008;102:56-61. (Pubitemid 351799457)
79. Muskat Y, Bukovsky I, Schneider D, Langer R. The use of scopolamine in the treatment of detrusor instability. J Urol. 1996;156:1989-90. (Pubitemid 26378033)
80. Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anti-cholinergic drugs: longitudinal cohort study. BMJ. 2006; 332:455-9.
81. Hashimoto M, Imamura T, Tanimukai S, et al. Urinary incontinence: an unrecognised adverse effect with donepe-zil. Lancet. 2000;356:568. (Pubitemid 30611868)
82. Kato K, Furuhashi K, Suzuki K, et al. Overactive bladder and glaucoma: a survey at outpatient clinics in Japan. Int J Urol. 2007;14:595-7. (Pubitemid 47084110)
83. Fink AM, Aylward GW. Buscopan and glaucoma: a survey of current practice. Clin Radiol. 1995;50:160-4.
84. Hollister LE. Current antidepressants. Annu Rev Pharmacol Toxicol. 1986;26:23-37. (Pubitemid 16090952)
85. Thor KB, Katofiasc MA. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther. 1995;274:1014-24.
86. Steers WD, Herschorn S, Kreder KJ. Duloxetine compared with placebo for treating women with symptoms of over-active bladder. BJU Int. 2007;100:337-45. (Pubitemid 47036580)
87. Olubadewo J. The effect of imipramine on rate detrusor muscle contractility. Arch Int Pharmacodyn Ther. 1980; 145:84-94. (Pubitemid 10090537)
88. Foreman MM, McNulty AM. Alterations in K(+)-evoked release of 3H-norepinephrine and contractile responses in urethral and bladder tissues induced by norepinephrine reuptake inhibition. Life Sci. 1993;53:193-200.
89. Castleden CM, George CF, Renwick AG, et al. Imipramine-a possible alternative to current therapy for urinary incontinence in elderly. J Urol. 1981;125:318-20. (Pubitemid 11143528)
90. Raezer DM, Benson GS, Wein AJ, et al. The functional approach to the management of the pediatric neuropathic bladder: a clinical study. J Urol. 1977;117:649-54. (Pubitemid 8113715)
91. Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Synder T. Postmenopausal hormones and incontinence: the Heart and Estrogen/progestin Replacement Study. Obstet Gynaecol. 2001;97:116-20. (Pubitemid 32057168)
92. Grodstein F, Lifford K, Resnick NM, Curhan GC. Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynaecol. 2004;103:254-60.
93. Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005;293:935-48. (Pubitemid 40271125)
94. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women ' s Health Initiative Investigators. Risks and benefi ts of estrogen plus progestin in healthy postmenopausal women: principal results From the Women ' s Health Initiative randomized controlled trial. JAMA. 2002;288: 321-33. (Pubitemid 34761611)
95. Samsioe G, Jansson I, Mellstr ö m D, Svanborg A. Occurrence, nature and treatment of urinary incontinence in a 70-year-old female population. Maturitas. 1985;7:335-42. (Pubitemid 16197523)
96. Cardozo L, Rekers H, Tapp A, et al. Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas. 1993;18:47-53. (Pubitemid 24037142)
97. Cardozo LD, Wise BG, Benness CJ. Vaginal oestradiol for the treatment of lower urinary tract symptoms in postmenopausal women-a double-blind placebo-controlled study. J Obstet Gynaecol. 2001;21:383-5. (Pubitemid 32735275)
98. Eriksen PS, Rasmussen H. Low dose 17 beta oestradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstet Gynaecol Reprod Biol. 1992;44:137-44.
99. Cardozo L, Lose G, McClish D, Versi E. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand. 2004; 83:892-7. (Pubitemid 39331534)
100. Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women. Cochrane Database Syst Rev. 2003; 2:CD001405.
101. Long CY, Liu CM, Hsu SC, Chen YH, Wu CH, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women. Fertil Steril. 2006; 85:155-60.
102. Schurch B, Schmid DM, St ö hrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med. 2000;342:665. (Pubitemid 30118430)
103. Reitz A, St ö hrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004;45: 510-5. (Pubitemid 38376219)
104. Dmochowski R, Sand PK. Botulinum toxin A in the overactive bladder: current status and future directions. BJU Int. 2007;99:247-62. (Pubitemid 46103100)
105. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007;177:2231-6. (Pubitemid 46726400)
106. Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol. 2007;62:452-7. (Pubitemid 350308769)
107. Reitz A, Denys P, Fermanian C, et al. Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol. 2007;52:1729-35. (Pubitemid 350064538)
108. Schmid D, Sauermann P, Werner M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol. 2006;176:177-85. (Pubitemid 43815416)
109. Duthie J, Wilson DI, Herbison G P. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev. 2007;3:CD005493.
110. Rashbaum M, Mandelbaum CC. Non-operative treatment of urinary incontinence in women. Am J Obstet Gynecol. 1948;56:777.
111. Diokno AC, Taub M. Ephedrine in treatment of urinary incontinence. Urology. 1975;5:624-5.
112. Alhasso A, Glazener CMA, Pickard R, et al. Adrenergic drugs for urinary incontinence in adults. Cochrane Database Syst Rev. 2005;3:CD001842.
113. Fraser MO, Chancellor MB. Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence. BJU Int. 2003;91:743-8. (Pubitemid 36577989)
114. Dmochowski RR, Miklos JR, Norton PA, et al. Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol. 2003;170(4 Pt 1): 1259-63. (Pubitemid 37108127)
115. Mariappan P, Alhasso A, Ballantyne Z, et al. Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. Eur Urol. 2007;51:67-74. (Pubitemid 44821531)
116. Gilja I, Radej M, Kovacic M, et al. Conservative treatment of female stress incontinence with imipramine. J Urol. 1984;132:909-11. (Pubitemid 14023499)
117. Fantl JA, Cardozo L, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1994;83: 12-18. (Pubitemid 24027373)
118. Sultana CJ, Walters MD. Estrogen and urinary incontinence in women. Maturitas. 1995;20:129-38.
119. Fantl JA, Bump RC, Robinson D, McClish DK, Wyman JF. Efficacy of oestrogen supplementation in the treatment of urinary incontinence. Obstet Gynaecol. 1996;88:745-9. (Pubitemid 26360811)
120. Jackson S, Shepherd A, Brookes S, Abrams P. The effect of oestrogen supplementation on post-menopausal urinary stress incontinence: a double-blind, placebo controlled trial. Br J Obstet Gynaecol. 1999;106:711-8. (Pubitemid 29304395)
121. Al-Badr A, Ross S, Soroka D, Drutz HP. What is the available evidence for hormone replacement therapy in women with stress urinary incontinence? J Obstet Gynaecol Can. 2003;25:567-74.
122. Matthiesen TB, Rittig S, N ø rgaard JP, et al. Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms. J Urol. 1996;156:1292-9. (Pubitemid 26307597)
123. N ø rgaard JP, Rittig S, Djurhuus JC. Nocturnal enuresis: an approach to treatment based on pathogenesis. J Pediatr. 1989;114(4 Pt 2):705-10. (Pubitemid 19098313)
124. Valiquette G, Herbert J, Maede-D ' Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol. 1996;53:1270-5. (Pubitemid 26425073)
125. Hashim H, Abrams P. Desmopreesin for the treatment of adult nocturia. Therapy. 2008;5:667-83.
126. Hashim H, Malmberg L, Graugaard-Jensen C. Desmo-pressin, as a ' designer-drug, ' in the treatment of overactive bladder syndrome. Neurourol Urodyn. 2009;28:40-6.
127. Rembratt A, Riis A, Norgaard J P. Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol Urodyn. 2006;25:105-9.
128. Marion, DW. Desmopressin: Drug information. In: UpToDate, Basow, DS (Ed), Waltham, MA, 2011.